Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Accured Expenses (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Change in Accured Expenses for 16 consecutive years, with -$13.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 75.54% year-over-year to -$13.5 million, compared with a TTM value of $35.7 million through Dec 2025, up 48.58%, and an annual FY2025 reading of $41.5 million, up 29.21% over the prior year.
  • Change in Accured Expenses was -$13.5 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $33.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $33.5 million in Q3 2025 and bottomed at -$20.1 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $2.8 million, with a median of -$1.0 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses plummeted 1985.05% in 2024, then skyrocketed 6451.31% in 2025.
  • Year by year, Change in Accured Expenses stood at -$2.3 million in 2021, then tumbled by 214.54% to -$7.2 million in 2022, then surged by 105.66% to $408000.0 in 2023, then tumbled by 1985.05% to -$7.7 million in 2024, then crashed by 75.54% to -$13.5 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ARWR at -$13.5 million in Q4 2025, $33.5 million in Q3 2025, and -$11.0 million in Q2 2025.